Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

LFVN

Lifevantage Corp

Healthcare · Pharmaceutical Preparations

$6.32Sep 29, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

Lifevantage Corp shows decelerating business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue -25% YoY in Q1 FY2026.

TrajectoryDecelerating

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue -25% YoY in Q1 FY2026

Pipeline evidence · 0d ago

LFVN's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on LFVN.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q1 2026

Full LFVN earnings analysis

Reported figures for Lifevantage Corp — research only, not investment advice.

Revenue YoY
-25.2%
EPS YoY
-57.7%

Latest Intelligence

Updated

What happened recently for Lifevantage Corp (LFVN) — events, not interpretation.

Event
Reported Q1 2026 revenue -25% YoY.
Also
Last session September 29, 2026 at $6.32.
Source
Q1 2026 earnings

Research & analysis only — not investment advice.

Loading earnings intelligence…

Lifevantage Corp (LFVN)

Healthcare · Pharmaceutical Preparations

Investment Snapshot above is the primary AlphaOS analysis for Lifevantage Corp — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Market cap:
$79.17M
Revenue:
$43.72M

LFVN earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow Lifevantage Corp through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.